<DOC>
	<DOCNO>NCT00811200</DOCNO>
	<brief_summary>The purpose study demonstrate statistically significant improvement visual acuity treatment use either Lucentis速 Triamcinolone速 compare treatment , patient radiation retinopathy .</brief_summary>
	<brief_title>Treatment Of Radiation Retinopathy Trial</brief_title>
	<detailed_description>Approximately 30-40 % patient develop deterioration visual acuity within 5 year treatment uveal melanoma use radiation therapy TTT due radiation retinopathy ( Shields 2002 , Bartlema 2003 ) . By administration either Lucentis速 Triamcinolone速 hope treat complication radiation therapy , demonstrate statistically significant improvement visual acuity reduce amount macular edema vascular leakage . Additionally , hope obtain good understand pathophysiologic process involve , demonstrate possible relation high level angiogenic factor ( VEGF ) anterior chamber fluid , radiation retinopathy . In conclusion , hope provide evidence new therapy patient retinopathy , due radiation uveal melanoma . There scientifically proven treatment available time .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>The eye previously irradiate treatment uveal melanoma ; Decrease visual acuity irradiation therapy 10 letter ( ETDRS ) 20/40 less ; Vision decrease consider due central radiation retinopathy significant macular edema optic disc edema ; Age 18 year old ; The patient fully competent ; Written inform consent participate trial give . Patient pregnant ( fertile ) willing use contraceptive duration trial ( one year ) Patient willing able return followup . Vision decrease consider due ischemic radiation retinopathy without macular edema optic disc edema ; Other , approved therapy indicate treatment condition ; Presence metastasis ; Evidence significant clinical disorder laboratory find make undesirable patient participate trial ; Preexisting retinopathy due disorder ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>radiation</keyword>
	<keyword>retinopathy</keyword>
	<keyword>maculopathy</keyword>
	<keyword>choroidopathy</keyword>
	<keyword>uveal</keyword>
	<keyword>melanoma</keyword>
	<keyword>lucentis</keyword>
	<keyword>ranibizumab</keyword>
	<keyword>kenalog</keyword>
	<keyword>triamcinolone acetonide</keyword>
	<keyword>radiation retinopathy irradiation uveal melanoma</keyword>
	<keyword>radiation maculopathy irradiation uveal melanoma</keyword>
	<keyword>radiation choroidopathy irradiation uveal melanoma</keyword>
</DOC>